Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Learn this powerful energy healing method.
Popular Articles
Cellulite Treatment

Prostate-Specific Antigen: To Test Or Not To Test, From Harvard Men's Health Watch
One of the most controversial issues in men"s health is whether men should routinely have a blood test for prostate-specific antigen (PSA) to screen for prostate cancer. Some experts argue that PSA testing saves lives by helping detect this common form of cancer early. Others say it triggers unnecessary treatment that disrupts many more lives than it saves. The results of two studies released this spring focused the debate, but scientists are still a long way from concluding the discussion, reports the July 2009 issue of Harvard Men"s Health Watch.
generic viagra online
Promedior Initiates Phase 1 Clinical Trial Of PRM-151, A Novel Compound For The Treatment Of Fibrotic Diseases And Tissue Remodeling
Promedior, Inc. announced the initiation of a Phase 1 clinical trial of PRM-151, a novel compound in development for the treatment of fibrotic diseases and tissue remodeling. The Phase 1 dose escalation study is designed to evaluate the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of ascending single intravenous doses of PRM-151 in healthy subjects. The study is being conducted at the Centre for Human Drug Research in The Netherlands.
News of the day
Physicians Can Lead Health Care Reform Through Payment And Delivery System Reforms
Physicians can and should play a leading role in achieving health care reform by working towards comprehensive reform of the way health care is paid for and delivered, helping achieve a guaranteed 1.5 percent annual savings in health care costs that would pay for covering all Americans, according to a New England Journal of Medicine Perspective piece published online.
Diagnostics

Merck Issues Statement On WHO Study Showing First Evidence That Elimination Of River Blindness Is Feasible In Africa

Merck & Co., Inc. issued the following statement in response to study results published today by the World Health Organization offering the first evidence that elimination of the tropical disease river blindness (onchocerciasis) in Africa is feasible with treatment with ivermectin (registered trademark Mectizan®). As the discoverer and manufacturer of Mectizan, Merck decided in 1987 to donate the drug to all who need it for as long as necessary until river blindness is eliminated as a public health problem. The Merck Mectizan Donation Program is one of the longest-running disease-specific drug donation and public/private partnership programs in history. "When Merck made the decision more than 20 years ago to donate Mectizan to help fight river blindness, we dreamed that a milestone like this might some day be possible," said Richard T. Clark, chairman, president and CEO, Merck & Co., Inc. "It gives me and thousands of Merck employees and retirees enormous satisfaction and pride to know we are playing a role in eliminating a dreaded disease that has ravaged villages and millions of people and generations of families." Since the program"s inception, Merck has donated 2.5 billion tablets of Mectizan at an estimated value of $3.75 billion. Recently, Merck pledged up to $25 million in support of an initiative with the World Bank, the World Health Organization and other partners to eliminate the disease in Africa. The Mectizan Donation Program now reaches more than 80 million people in Africa, Latin America and Yemen annually. For more information about the Merck Mectizan Donation Program and Merck"s corporate responsibility efforts, visit here. Merck


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009